Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 13/20 | 0.76 |
| ▸ | PLG | P00747 | 7/20 | 0.62 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.62 |
| ▸ | PRSS2 | P07478 | 7/20 | 0.62 |
| ▸ | PRSS3 | P35030 | 7/20 | 0.62 |
| ▸ | PLAU | P00749 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29679057 | 1.00 | FOLH1 (0.76) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL29679477 | 1.00 | FOLH1 (0.76) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL26090338 | 1.00 | FOLH1 (0.76) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL28659047 | 1.00 | FOLH1 (0.76) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL22883093 | 0.93 | FOLH1 (0.75) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL19296397 | 0.92 | FOLH1 (0.76) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL27303660 | 0.92 | FOLH1 (0.73) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL26178698 | 0.92 | FOLH1 (0.78) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL26001462 | 0.92 | FOLH1 (0.78) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL22883091 | 0.91 | FOLH1 (0.72) | FOLH1PLGPRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250222143-A1 | TARGETED RADIOTHERANOSTICS BASED ON POLYAZAMACROCYCLIC, MIXED-DONOR SCAFFOLDS LINKED TO A TARGETING VECTOR | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-07-10 | — | — | US | claimed |
| WO-2023070004-A1 | TARGETED RADIOTHERANOSTICS BASED ON POLYAZAMACROCYCLIC, MIXED-DONOR SCAFFOLDS LINKED TO A TARGETING VECTOR | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-04-27 | — | — | WO | claimed |
| US-20250222143-A1 | TARGETED RADIOTHERANOSTICS BASED ON POLYAZAMACROCYCLIC, MIXED-DONOR SCAFFOLDS LINKED TO A TARGETING VECTOR | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-07-10 | — | — | US | disclosed |
| WO-2023070004-A1 | TARGETED RADIOTHERANOSTICS BASED ON POLYAZAMACROCYCLIC, MIXED-DONOR SCAFFOLDS LINKED TO A TARGETING VECTOR | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023070004-A1 | TARGETED RADIOTHERANOSTICS BASED ON POLYAZAMACROCYCLIC, MIXED-DONOR SCAFFOLDS LINKED TO A TARGETING VECTOR | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-04-27 | — | — | WO | disclosed |
| US-11547767-B2 | 99mTc-EDDA/HYNIC-iPSMA as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen | INSTITUTO NACIONAL DE INVESTIGACIONES NUCLEARES (MX) | 2023-01-10 | — | — | US | disclosed |
| CN-113747927-A | Prostate Specific Membrane Antigen (PSMA) ligands comprising an amylase cleavable linker | 德国癌症研究中心 | 2021-12-03 | — | — | CN | disclosed |
| US-20210187132-A1 | 99MTC-EDDA/HYNIC-IPSMA AS A RADIOPHARMACEUTICAL FOR DETECTING THE OVEREXPRESSION OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN | INSTITUTO NACIONAL DE INVESTIGACIONES NUCLEARES (MX) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210187132-A1 | 99MTC-EDDA/HYNIC-IPSMA AS A RADIOPHARMACEUTICAL FOR DETECTING THE OVEREXPRESSION OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN | KLK3, EPS15, CD99 | FOLH1 21/4885PLG 3524/4885PRSS1 1265/4885 |
| US-20250222143-A1 | TARGETED RADIOTHERANOSTICS BASED ON POLYAZAMACROCYCLIC, MIXED-DONOR SCAFFOLDS LINKED TO A TARGETING VECTOR | PAICS, RABGGTB, PARP1 | FOLH1 138/4885PLG 3803/4885PRSS1 2512/4885 |
| US-11547767-B2 | 99mTc-EDDA/HYNIC-iPSMA as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen | KLK3, EPS15, CD99 | FOLH1 21/4885PLG 3524/4885PRSS1 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.